{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT02161783",
            "orgStudyIdInfo": {
                "id": "2013OC003"
            },
            "secondaryIdInfos": [
                {
                    "id": "MT2013-06C",
                    "type": "OTHER",
                    "domain": "University of Minnesota Blood and Marrow Transplant Program"
                }
            ],
            "organization": {
                "fullName": "Masonic Cancer Center, University of Minnesota",
                "class": "OTHER"
            },
            "briefTitle": "Treatment of Graft Failure After Hematopoietic Stem Cell Transplantation",
            "officialTitle": "Treatment of Graft Failure After Hematopoietic Stem Cell Transplantation",
            "therapeuticArea": [
                "Other"
            ],
            "study": "treatment-of-graft-failure-after-hematopoietic-stem-cell-transplantation"
        },
        "statusModule": {
            "statusVerifiedDate": "2023-12",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2014-10-06",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2032-01-24",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2032-01-30",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2014-06-10",
            "studyFirstSubmitQcDate": "2014-06-10",
            "studyFirstPostDateStruct": {
                "date": "2014-06-12",
                "type": "ESTIMATED"
            },
            "lastUpdateSubmitDate": "2023-12-15",
            "lastUpdatePostDateStruct": {
                "date": "2023-12-18",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "Masonic Cancer Center, University of Minnesota",
                "class": "OTHER"
            }
        },
        "oversightModule": {
            "oversightHasDmc": true
        },
        "descriptionModule": {
            "briefSummary": "This is a guideline for the treatment of graft failure after hematopoietic stem cell transplant (HSCT). This regimen, consisting of cyclophosphamide and fludarabine with low dose total body irradiation (TBI) is designed to promote donor engraftment by day 42 after initial graft failure.\n\nThe graft will consist of bone marrow or G-CSF mobilized peripheral blood from a haploidentical related donor. The source of stem cells will be determined by the transplant team based on factors such as patient's age, medical history, donor availability and will be according to the current University of Minnesota Blood and Marrow Transplantation Program selection guidelines."
        },
        "conditionsModule": {
            "conditions": [
                "Primary Graft Failure",
                "Secondary Graft Failure"
            ],
            "keywords": [
                "Hematopoietic stem cell transplant"
            ]
        },
        "designModule": {
            "studyType": "OBSERVATIONAL",
            "patientRegistry": false,
            "designInfo": {
                "observationalModel": "COHORT",
                "timePerspective": "PROSPECTIVE"
            },
            "enrollmentInfo": {
                "count": 50,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Treatment",
                    "description": "This regimen consists of cyclophosphamide and fludarabine with low dose total body irradiation (TBI), followed by hematopoietic stem cell infusion.",
                    "interventionNames": [
                        "Drug: Fludarabine",
                        "Drug: Cyclophosphamide",
                        "Radiation: Total Body Irradiation",
                        "Biological: Hematopoietic stem cell infusion"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "Fludarabine",
                    "description": "Fludarabine 30 mg/m2 IV over 1 hour given on days -6 through -2 of transplant.",
                    "armGroupLabels": [
                        "Treatment"
                    ],
                    "otherNames": [
                        "Fludara"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Cyclophosphamide",
                    "description": "Cyclophosphamide 14.5 mg/kg IV over 1-2 hours given on days -6 and -5 from transplant. And Cyclophosphamide 50 mg/kg IV over 2 hours given on days +3 and +4 from transplant.",
                    "armGroupLabels": [
                        "Treatment"
                    ]
                },
                {
                    "type": "RADIATION",
                    "name": "Total Body Irradiation",
                    "description": "TBI 200cGy in a single fraction on day -1 from transplant.",
                    "armGroupLabels": [
                        "Treatment"
                    ],
                    "otherNames": [
                        "TBI"
                    ]
                },
                {
                    "type": "BIOLOGICAL",
                    "name": "Hematopoietic stem cell infusion",
                    "description": "Hematopoietic stem cell infusion given on day 0.",
                    "armGroupLabels": [
                        "Treatment"
                    ],
                    "otherNames": [
                        "HSCT"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Rate of donor engraftment",
                    "description": "Rate of sustained donor engraftment at day 42 post this transplant.",
                    "timeFrame": "day 42"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Rate of treatment related mortality",
                    "description": "Rate of treatment related mortality (TRM) at day 100",
                    "timeFrame": "day 100"
                },
                {
                    "measure": "Rate of survival",
                    "description": "Rate of survival by day 100.",
                    "timeFrame": "Day 100"
                },
                {
                    "measure": "Rate of survival",
                    "description": "Rate of survival at 1 year",
                    "timeFrame": "1 year"
                },
                {
                    "measure": "Incidence of acute graft-versus-host disease",
                    "description": "Incidence of acute graft-versus-host disease by day 100",
                    "timeFrame": "Day 100"
                },
                {
                    "measure": "Incidence of chronic graft-versus-host disease",
                    "description": "Incidence of chronic graft-versus-host disease at 1 year.",
                    "timeFrame": "1 year"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* Patients with primary or secondary graft failure, as defined below, may receive a second transplant:\n\n  * Primary graft failure is defined as not achieving an ANC \u22650.5x10\\^9/L for three consecutive days by day 35 - 42 following the first transplant.\n  * Secondary graft failure is defined as achieving an ANC \u22650.5x10\\^9/L for three consecutive days by day 35 - 42, but subsequently drops below 0.5x10\\^9/L without recovery.\n  * Loss of chimerism is defined as achieving an ANC \u22650.5x10\\^9/L for three consecutive, but with less than 10% CD15+ donor cells in the marrow or peripheral blood.\n* Recipients should have acceptable organ function defined as:\n\n  * Renal: creatinine \\< 2.0 (adults) and creatinine clearance \\> 30. For creatinine clearance \\< 70, consultation with a BMT pharmacist is necessary for chemotherapy dose adjustments.\n  * Hepatic: bilirubin, AST/ALT, ALP \\< 10 x upper limit of normal\n  * Cardiac: left ventricular ejection fraction \\> 40%\n\nExclusion Criteria:\n\n* Uncontrolled infection at the time of transplant.\n* Patients with Fanconi Anemia or other DNA breakage syndromes.",
            "healthyVolunteers": false,
            "sex": "ALL",
            "stdAges": [
                "CHILD",
                "ADULT",
                "OLDER_ADULT"
            ],
            "studyPopulation": "Graft failure for",
            "samplingMethod": "NON_PROBABILITY_SAMPLE"
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Timothy Krepski",
                    "role": "CONTACT",
                    "phone": "612-273-2800",
                    "email": "tkrepsk1@fairview.org"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Troy C Lund, MD, PhD",
                    "affiliation": "University of Minnesota",
                    "role": "PRINCIPAL_INVESTIGATOR"
                }
            ],
            "locations": [
                {
                    "facility": "University of Minnesota Medical Center, Fairview",
                    "status": "RECRUITING",
                    "city": "Minneapolis",
                    "state": "Minnesota",
                    "zip": "55455",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Timothy Krepski",
                            "role": "CONTACT",
                            "phone": "612-273-2800",
                            "email": "tkrepsk1@fairview.org"
                        },
                        {
                            "name": "Troy C Lund, MD, PhD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 44.97997,
                        "lon": -93.26384
                    }
                }
            ]
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "browseLeaves": [
                {
                    "id": "M12307",
                    "name": "Neoplasm Metastasis",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC04",
                    "name": "Neoplasms"
                },
                {
                    "abbrev": "BC23",
                    "name": "Symptoms and General Pathology"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                }
            ]
        },
        "interventionBrowseModule": {
            "meshes": [
                {
                    "id": "D000003520",
                    "term": "Cyclophosphamide"
                },
                {
                    "id": "C000024352",
                    "term": "Fludarabine"
                }
            ],
            "ancestors": [
                {
                    "id": "D000007166",
                    "term": "Immunosuppressive Agents"
                },
                {
                    "id": "D000007155",
                    "term": "Immunologic Factors"
                },
                {
                    "id": "D000045505",
                    "term": "Physiological Effects of Drugs"
                },
                {
                    "id": "D000018501",
                    "term": "Antirheumatic Agents"
                },
                {
                    "id": "D000018906",
                    "term": "Antineoplastic Agents, Alkylating"
                },
                {
                    "id": "D000000477",
                    "term": "Alkylating Agents"
                },
                {
                    "id": "D000045504",
                    "term": "Molecular Mechanisms of Pharmacological Action"
                },
                {
                    "id": "D000000970",
                    "term": "Antineoplastic Agents"
                },
                {
                    "id": "D000019653",
                    "term": "Myeloablative Agonists"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M6727",
                    "name": "Cyclophosphamide",
                    "asFound": "Effect of",
                    "relevance": "HIGH"
                },
                {
                    "id": "M283230",
                    "name": "Fludarabine",
                    "asFound": "Rate",
                    "relevance": "HIGH"
                },
                {
                    "id": "M225513",
                    "name": "Fludarabine phosphate",
                    "relevance": "LOW"
                },
                {
                    "id": "M10212",
                    "name": "Immunosuppressive Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M10201",
                    "name": "Immunologic Factors",
                    "relevance": "LOW"
                },
                {
                    "id": "M20604",
                    "name": "Antirheumatic Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M20942",
                    "name": "Antineoplastic Agents, Alkylating",
                    "relevance": "LOW"
                },
                {
                    "id": "M3820",
                    "name": "Alkylating Agents",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "ANeo",
                    "name": "Antineoplastic Agents"
                },
                {
                    "abbrev": "ARhu",
                    "name": "Antirheumatic Agents"
                },
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                }
            ]
        }
    },
    "hasResults": false
}